Biomarker Discovery and Validation
Traditional “Omics” approaches to biomarker validation have significant constraints.
Biomarker Discovery and Validation
Traditional “Omics” approaches to biomarker validation have significant constraints.
GENOMICS
Genomics is not dynamic. Does not measure life.
GENOMICS
Genomics is not dynamic. Does not measure life.
TRANSCRIPTOMICS
Transcriptomics is limited in depth and limited to gene expression. It misses changes that happen to proteins.
TRANSCRIPTOMICS
Transcriptomics is limited in depth and limited to gene expression. It misses changes that happen to proteins.
PROTEOMICS
Limited in depth and difficulty to quantify. Costly and time consuming.
PROTEOMICS
Limited in depth and difficulty to quantify. Costly and time consuming.
The Next Generation of Proteomics Involves DNA
Other novel proteomics platforms translate the relative abundance of proteins in a sample to DNA sequences. This translation of information enables more reliable and cost-effective results by reading the information with next generation sequencing or qPCR analysis
These platforms still contain implicit constraints:
- They are limited to canonical forms of proteins.
- The oligo probes are propriety and not available for end-user applications.
The Next Generation of Proteomics Involves DNA
Other novel proteomics platforms translate the relative abundance of proteins in a sample to DNA sequences. This translation of information enables more reliable and cost-effective results by reading the information with next generation sequencing or qPCR analysis
These platforms still contain implicit constraints:
- They are limited to canonical forms of proteins.
- The oligo probes are propriety and not available for end-user applications.
Our Aptamarker platform overcomes these constraints
Aptamarkers can bind canonical proteins in their native state in plasma or tissue.
Aptamarkers can bind to protein complexes, protein misfoldings, isoforms, cleave events, ion-loadings, complexed with drugs, post-translation modifications and protein fragments.
Aptamarkers can bind to extra-cellular vesicles, metabolites and non-coding RNA
Aptamarkers allows end-users access to the oligo probes for diagnostic development.
Our Aptamarker platform overcomes these constraints
Aptamarkers can bind canonical proteins in their native state in plasma or tissue.
Aptamarkers can bind to protein complexes, protein misfoldings, isoforms, cleave events, ion-loadings, complexed with drugs, post-translation modifications and protein fragments.
Aptamarkers can bind to extra-cellular vesicles, metabolites and non-coding RNA
Aptamarkers allows end-users access to the oligo probes for diagnostic development.
The Aptamarker Platform is enabled by combining two proprietary inventions
1.) FRELEX selection
FRELEX is our patented system for selecting aptamers that bind to target molecules in their free state. This process enables partitioning of bound aptamers from unbound without a need to immobilize targets. FRELEX enables the selection of Aptamarkers for proteins in their native state in plasma or in tissue, including in complexes (dimers, trimers, etc), foldings, ion-loadings, complexed with drugs, and protein fragments.
The Aptamarker Platform is enabled by combining two proprietary inventions
1.) FRELEX selection
FRELEX is our patented system for selecting aptamers that bind to target molecules in their free state. This process enables partitioning of bound aptamers from unbound without a need to immobilize targets. FRELEX enables the selection of Aptamarkers for proteins in their native state in plasma or in tissue, including in complexes (dimers, trimers, etc), foldings, ion-loadings, complexed with drugs, and protein fragments.
2.) Closed Sequence Neomer Library
We have developed the NEOMER selection method for aptamer discovery. We have designed a closed system with a defined set of sequences in our library with higher structural diversity that found in a SELEX library. This enables the selection of the same set of sequences on different targets and reduces the selection rounds to a single step.
The neomer approach to Aptamarkers improves on existing next generation proteomics platforms by;
- Providing a deeper analysis, more proteins, and more protein forms.
- Assaying non-canonical forms of proteins
- Improving simplicity, one step selection and NGS analysis.
- Decreasing cost, no creation of complex arrays of probes, just a reproducible library.
2.) Closed Sequence Neomer Library
We have developed the NEOMER selection method for aptamer discovery. We have designed a closed system with a defined set of sequences in our library with higher structural diversity that found in a SELEX library. This enables the selection of the same set of sequences on different targets and reduces the selection rounds to a single step.
The neomer approach to Aptamarkers improves on existing next generation proteomics platforms by;
- Providing a deeper analysis, more proteins, and more protein forms.
- Assaying non-canonical forms of proteins
- Improving simplicity, one step selection and NGS analysis.
- Decreasing cost, no creation of complex arrays of probes, just a reproducible library.
We have validated the Aptamarker approach with the development of a blood test for brain amyloid.
We have validated the Aptamarker approach with the development of a blood test for brain amyloid.
Direct application of Aptamarkers with qPCR diagnostic kits
Direct application of Aptamarkers with qPCR diagnostic kits
Aptamarker Use Cases
- Biomarkers in biofluids or tissue on slides for any disease
- Agnostic screening with capacity to characterize targets of biomarkers
- Patient stratification
- Exclusion (identification of patients with predisposition to side effects or lack of response)
- Inclusion (enrollment of patients with predisposition for treatment response)
- Off-target toxicity prediction
- Prediction of side effect response
- Translation from animal models
- Target engagement characterization
- Mapping drug binding sites
- Developing dynamic tests for on/off rates
- Biomarkers in biofluids or tissue on slides for any disease
The Aptamarker platform is available exclusively through NeoVentures Biotechnology Europe
Aptamarker Use Cases
- Biomarkers in biofluids or tissue on slides for any disease
- Agnostic screening with capacity to characterize targets of biomarkers
- Patient stratification
- Exclusion (identification of patients with predisposition to side effects or lack of response)
- Inclusion (enrollment of patients with predisposition for treatment response)
- Off-target toxicity prediction
- Prediction of side effect response
- Translation from animal models
- Target engagement characterization
- Mapping drug binding sites
- Developing dynamic tests for on/off rates
- Biomarkers in biofluids or tissue on slides for any disease
The Aptamarker platform is available exclusively through NeoVentures Biotechnology Europe
Please contact us to discuss
Applications to your specific projects, incorporation of approach in grant proposals or additional use cases.
Please contact us to discuss
Applications to your specific projects, incorporation of approach in grant proposals or additional use cases.
Watch Dr. Gregory Penner's Presentation
Neomers:
A Reproducible Aptamer Selection Method
This conference took place on April 4th at Aptamers 2022.
Dr. Gregory Penner introduced our game-changing new method of aptamer selection. Hear what he has to say about it by watching the full presentation.
Fill in the form for instant access.
Get Instant Access Now
Watch Dr. Gregory Penner's Presentation
Neomers:
A Reproducible Aptamer Selection Method
This conference took place on April 4th at Aptamers 2022.
Dr. Gregory Penner introduced our game-changing new method of aptamer selection. Hear what he has to say about it by watching the full presentation.
Fill in the form for instant access.
English 
French 
Spanish